Form 4: Amgen Director Michael V. Drake Acquires Shares

Amgen Inc. Director Michael V. Drake acquired 79.6444 shares of common stock via dividend equivalents.

Summary

• Director Michael V. Drake acquired 79.6444 shares of Amgen Inc. (AMGN) common stock on May 5, 2026.
• The acquisition was made at a price of $0 per share, representing dividend equivalents (DEs) credited to existing unvested Restricted Stock Units.
• Following this transaction, the reporting person's total beneficial ownership increased to 5,109.2869 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine dividend reinvestment rather than a discretionary open-market purchase or sale.

Positives

• The transaction reflects the accumulation of equity through dividend reinvestment, signaling continued alignment between the director and shareholder interests.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable as this is a routine disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that this filing is a routine administrative disclosure regarding director compensation and equity holdings, common in the biotechnology sector to maintain transparency regarding insider ownership.

Comparison to Industry Standards

• The acquisition of shares via dividend equivalents is a standard practice for corporate directors in large-cap pharmaceutical companies like Amgen, Pfizer, and Gilead Sciences.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard equity incentive plan adjustment.

Next Steps

• None.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Transaction, Dividend Equivalents, Director Ownership